Danish-German test centre

12. Oct 2016
A central cornerstone of InnoCan is establishing a Danish-German test center. Its’ purpose is to help medtech companies develop and mature their innovative solutions for cancer patients, and this significantly faster than is the case today.

Easy access for medtech companies
Today it can take a long time for medtech companies to develop new products for health care as well as getting them approved and implemented. The test center will therefore work to ensure that companies have easy access to hospitals. This allows them to quickly test their solutions in a professional and interdisciplinary test environment. The test center can be accessed in both Denmark and Germany and the companies will therefore have the opportunity to test their products in both countries, so diverse requirements across the project region are identified. 

Focus on the patient
The goal is to examine how benefits for both cancer patients and their relatives can be achieved through the development of new technology. The test center will have a special focus on developing and implementing new solutions that can monitor the patient’s values during hospitalization and at home – e.g. pulse, temperature, breathing and blood pressure. The measurements can often be useful in early detection of disease or worsening of the patient’s condition. 

A Danish-German test center
The test center will work interdisciplinary on the basis of a Danish-German network of stakeholders with innovation oriented skills within technology, health and design. In the long run the cooperation will result in a more open cross-border market for health care benefits, where innovations and new methods of treatment quickly and effectively can be transferred to the clinical treatment and care in both countries. The ambition is for the project region to become a pioneer area for e-health and cross-bordering health benefits. 

Who is behind it all?
Production, Research and Innovation (PFI) in Region Zealand is in charge of this part of the project. In addition are the Departments of Oncology in Næstved, Odense, Kiel and Lübeck, which are test sites for testing and further development of the solutions. The Design School Kolding and University College Absalon contribute amongst other things to the development of the design and the specific test runs. 

Søren Tvilsted, PFI
+45 21 51 90 69